SOPHiA GENETICS and Strand Life Sciences Announce New Strategic Partnership
The companies will join forces to advance the use of precision medicine on a global scale BOSTON and ROLLE, Switzerland, April 4, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company in the healthcare space and a leader in data-driven medicine, today announced a s...
SOPHiA GENETICS and The French Kidney Cancer Research Network (UroCCR) Publish Results from Multiyear Collaboration
New Multimodal Algorithm Highlights Predictive Benefit Of Artificial Intelligence (AI) for Cancer Research BOSTON and ROLLE, Switzerland, March 15, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, and the French Kidney Can...
SOPHiA GENETICS and AstraZeneca Spain Commit to Increasing Ovarian Cancer Testing in Spain
SOPHiA GENETICS and AstraZeneca Spain expand HRD testing program to support molecular diagnosis of ovarian cancer inSpain BOSTON and ROLLE, Switzerland and MADRID, Feb. 7, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, t...
SOPHiA GENETICS and Karkinos Healthcare Forge Strategic Partnership to Advance Cancer Research in India
SOPHiA GENETICS technology helps advance cancer research across India SOPHiA GENETICS and Karkinos Healthcare join forces to propel cutting-edge genomic solutions for breakthroughs in personalized cancer care inIndia BOSTON and ROLLE, Switzerland, Jan. 15, 2024 /PRNewswire/ -- SOPHiA GENETICS (N...
The Institute of Human Genetics, Polish Academy of Sciences (IHG PAS) is Live on SOPHiA GENETICS
The SOPHiA DDM™ Platform used by IHG PAS to advance its research of male infertility BOSTON and ROLLE, Switzerland, Nov. 17, 2023 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today announced that the Institute of Human Gene...
SOPHiA GENETICS Enters New Collaboration with Memorial Sloan Kettering Cancer Center and AstraZeneca to Address Global Inequalities in Comprehensive Cancer Care
The three companies will collaborate to improve global access to advanced cancer testing and data, broadening access to cutting-edge science BOSTON and ROLLE, Switzerland, Oct. 18, 2023 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a category-defining software company and a global leader in da...
SOPHiA GENETICS Publishes Results of 2022 Annual General Meeting
BOSTON and LAUSANNE, Switzerland, June 16, 2022 /PRNewswire/ -- SOPHiA GENETICS SA (Nasdaq: SOPH) ("the Company"), is pleased to announce the Annual General Meeting ("the Meeting") was held at the Company's headquarters, rue du Centre 172, 1025 St-Sulpice, VD,Switzerland, earlier today at 2:00 p....
SOPHiA GENETICS Announces Nomination of Jean-Michel Cosséry to Board of Directors
BOSTON and LAUSANNE, Switzerland, May 5, 2022 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a leader in data-driven medicine, today announced the nomination of Jean-Michel Cosséry to its Board of Directors. The Board of Directors will propose the appointment of Mr. Cosséry as a member of the Bo...
SOPHiA GENETICS Hits Milestone of One Million Genomic Profiles Analyzed by the SOPHiA DDM™ Platform
BOSTON and LAUSANNE, Switzerland, April 26, 2022 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a leader in data-driven medicine, has reached the milestone of one million genomic profiles analyzed by its SOPHiA DDM™ Platform, securing its position as one of the largest knowledge sharing platform...
SOPHiA GENETICS and REALM IDx Sign Letter of Intent to Collaborate in Accelerating Cancer Research
The intended collaboration aims to help improve patient care by enhancing next-generation sequencing research for cancer care and expanding data sources for precision medicine. BOSTON, ALISO VIEJO, Calif. and LAUSANNE, Switzerland, March 14, 2022 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH) an...
SOPHiA GENETICS HRD Solution Adopted in Asia Pacific
BOSTON, LAUSANNE, Switzerland and TAIPEI CITY, Taiwan, March 9, 2022 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH) today announced that SOFIVA GENOMICS, which is one of the largest genetic testing companies inTaiwan aiming to provide genetic testing to clinicians, is the first institution inAsia...
SOPHiA GENETICS Launches New Deep Learning Capabilities to Support the Detection of Homologous Recombination Deficiencies
The SOPHiA DDM HRD Solution offers cost-effective, accurate, reliable, timely, and easily implementable in-house results to empower better clinical research decisions BOSTON and LAUSANNE, Switzerland, Feb. 24, 2022 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a leader in Data-Driven Medicine,...
First Japanese Institution to Utilize SOPHiA GENETICS' Myeloid Plus Solution
BOSTON, LAUSANNE, Switzerland, and HIROSHIMA, Japan, Feb. 22, 2022 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), today announced an agreement withHiroshima University, one of the top public universities inHiroshima City, Japan, to support their molecular profiling by next-generation sequencing ...
SOPHiA GENETICS Appoints Ken Freedman as Chief Revenue Officer
BOSTON and LAUSANNE, Switzerland, Jan. 26, 2022 /PRNewswire/ -- SOPHiA GENETICS SA (Nasdaq: SOPH), the creator of a global data pooling and knowledge sharing platform that democratizes data-driven medicine, today announced that Ken Freedman has been appointed Chief Revenue Officer. With a backgro...
SOPHiA GENETICS Reports Strong Traction in the Launch Phase of its DEEP-Lung-IV Multimodal Clinical Study
BOSTON and LAUSANNE, Switzerland, Jan. 11, 2022 /PRNewswire/ -- SOPHiA GENETICS SA (NASDAQ: SOPH), the creator of a global data pooling and knowledge sharing platform that advances data-driven medicine, announced today strong traction in the launch phase of their DEEP-Lung-IV clinical study (NCT0...
Executive Team Hires at SOPHiA GENETICS to Enhance BioPharma Business
BOSTON and LAUSANNE, Switzerland, Jan. 10, 2022 /PRNewswire/ -- SOPHiA GENETICS SA (Nasdaq: SOPH), the creator of a global data pooling and knowledge sharing platform that advances data-driven medicine, announced key additions to their leadership team with the hiring of Peter Casasanto as Chief B...
SOPHiA GENETICS Announces Launch of DEEP-Lung-IV Multimodal Clinical Study
Study to leverage deep learning-enabled analysis of the aggregation of real-world multimodal data to validate predictive signatures associated with response to immunotherapy and prognosis of patients with stage IV non-small cell lung cancer Large-scale, multicentric real-world study aims to enro...
SOPHiA GENETICS Hosts Symposium with GE Healthcare at RSNA 2021
Symposium to address how new AI-powered analytic and workflow solutions for clinical and biopharma markets are advancing data-driven medicine Symposium encapsulates SOPHiA GENETICS and GE Healthcare alliance to provide joint solutions and multimodal analytics to healthcare providers and biopharma...
SOPHiA GENETICS Launches SOPHiA DDM™ for SureSelect Human All Exon v8
New bioinformatic workflow advances analysis capabilities for whole exome assessment and interpretation BOSTON and LAUSANNE, Switzerland, Nov. 1, 2021 /PRNewswire/ -- SOPHiA GENETICS SA (Nasdaq: SOPH), the creator of a global data pooling and knowledge sharing platform that advances data-driven ...
SOPHiA GENETICS offers new genomic application for a deeper investigation of Mendelian diseases
SOPHiA Clinical Exome Solution v3 offers a streamlined end-to-end workflow to facilitate the assessment of challenging Mendelian disorders BOSTON and LAUSANNE, Switzerland, Oct. 13, 2021 /PRNewswire/ -- SOPHiA GENETICS SA (Nasdaq: SOPH), the creator of a global data pooling and knowledge sharing...
